

Dr. Grace Pavlath Joins CMT Research Foundation's Research Advisory Committee

Collectively, the RAC members represent decades of experience within the therapeutic and drug development space for CMT and other neurological diseases.

ATLANTA , GA, USA, November 14, 2023 /EINPresswire.com/ -- The [CMT Research Foundation](#) (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced that Dr. Grace Pavlath has joined its newly formed Research Advisory Committee (RAC). Other members include: Dr. William Motley (Rapport Therapeutics), Dr. Paul August (ReviR Therapeutics), Dr. Arthur Suckow, Co-founder and former Chief Executive Officer of DTx Pharma, and Dr. Charlotte Sumner (Johns Hopkins). Collectively, the RAC members represent decades of insights, experience, and accomplishments within the therapeutic and drug development space for CMT and other neurological diseases.



Dr. Grace Pavlath



**CMT
Research
Foundation**

CMT Research Foundation

The RAC is tasked with maintaining and enhancing scientific strategies that support the Foundation's singular mission to find treatments and cures for CMT. They will work closely with the Scientific Advisory Board to fine-tune project selection and prioritization in order to fund the types of research that have the greatest potential for impact. Moreover, they will provide scientific guidance to the Board of Directors.

"We are pleased to have Grace rejoin CMTRF," says Cleary Simpson, CMTRF's CEO. "She was our

first CSO and she led our approach to funding projects with the greatest impact."

Dr. Pavlath was Chief Scientific Officer for the CMT Research Foundation from July 2019 to May 2020 managing funded research projects while curating more projects and acting as the steward for all scientific efforts and funding allocation. Currently, she is Vice President, Translational Development for Solid Biosciences and before that was Vice President, Research. She was Vice President, Research at Aavanti Bio just prior to its merger with Solid Biosciences.

Dr. Pavlath served as Chief Research Officer for the Muscular Dystrophy Association (MDA) from 2014-2019. Prior to joining MDA, Dr. Pavlath led an internationally known laboratory as a tenured professor of Pharmacology at Emory University establishing herself as a leading researcher in cellular and molecular mechanisms involved in muscle regeneration and muscular dystrophy. She earned her doctorate in Pharmacology at Stanford University and then completed postdoctoral training at Stanford University and the University of Arizona.

CMT Research Foundation (CMTRF) is a patient-led, non-profit focused on delivering treatments and cures for CMT. The foundation identifies significant obstacles or deficiencies impeding progress towards a cure and seeks out collaborators to address these issues. It's our mission to raise funds to invest in promising science with high potential of leading to treatments and cures. Founded by two patients who are driven to expedite drug delivery to people who live with CMT, the 501(c)(3) federal tax-exempt organization is supported by personal and corporate financial gifts.

*Charcot-Marie-Tooth encompasses a group of inherited, chronic peripheral neuropathies that result in nerve degradation. CMT patients suffer from progressive muscle atrophy of legs and arms, causing walking, running and balance problems as well as abnormal functioning of hands and feet. CMT affects one in 2,500 people (about the same prevalence as cystic fibrosis), including 150,000 Americans and nearly 3 million people worldwide. At the moment, there is no treatment or cure for CMT.

George Simpson
CMT Research Foundation
+1 203-521-0352
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/668511289>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.